<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0301221550
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rozlytrek
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENTRECTINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3444.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Mayne Pharma Inc" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Mayne Pharma Inc
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3402]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Roche Products Saudi Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            F.Hoffmann-La Roche Ltd. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rozlytrek is a cancer medicine that contains the active substance entrectinib</p><p>It is a prescription medicine used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an abnormal ROS1 gene.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adults and children 12 years and older with solid tumors (cancer) that:</p><p>o&nbsp;&nbsp; &nbsp;are caused by certain abnormal NTRK genes and</p><p>o&nbsp;&nbsp; &nbsp;have spread or if surgery to remove their cancer is likely to cause severe complications, and</p><p>o&nbsp;&nbsp; &nbsp;there is no satisfactory alternative treatment option or the cancer grew or spread on other treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Before you take Rozlytrek, tell your healthcare provider about all of your medical conditions, including if you:</strong></p><ul><li>have liver or kidney problems</li><li>have any heart problems, including a condition called long QT syndrome</li><li>have nervous system (neurological) problems</li><li>have or have had eye or vision problems</li></ul><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>Rozlytrek</strong><strong> may cause serious side effects, including</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Congestive heart failure. </strong>Rozlytrek may cause congestive heart failure or make the congestive heart failure that you already have worse. Tell your healthcare provider right away if you have any of the following signs and symptoms of congestive heart failure:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent coughing or wheezing</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble breathing when lying down</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden weight gain</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increasing shortness of breath</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, weakness, or fatigue</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in ankles, feet, or legs</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Central nervous system (CNS) effects. </strong>Rozlytrek may cause dizziness, changes in your mood, or may affect how you think and cause confusion, hallucinations, and problems with concentration, attention, memory, and sleep. Tell your healthcare provider right away if you have any of these symptoms.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bone fractures.</strong> Rozlytrek may increase your risk for bone fractures. Bone fractures may happen with or without a fall or other injury. Tell your healthcare provider if you have pain, changes in movement, or bone abnormalities.&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver problems (hepatotoxicity). </strong>Your healthcare provider will do blood tests to check your liver function during treatment with Rozlytrek. Tell your healthcare provider right away if you develop symptoms of liver problems including: loss of appetite, nausea or vomiting, or pain on the upper right side of your stomach area. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop Rozlytrek if you develop liver problems with Rozlytrek.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Increased uric acid level in your blood (hyperuricemia).</strong> Rozlytrek may cause an excess of uric acid in your blood. Your healthcare provider may do tests before and during your treatment with Rozlytrek to check the uric acid level in your blood. Your healthcare provider may prescribe medications if you have high blood uric acid levels.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Changes in the electrical activity of your heart called QT prolongation</strong>. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider will do tests before and during your treatment with Rozlytrek to check the electrical activity of your heart and your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, lightheaded, dizzy, or feel your heart beating irregularly or fast during your treatment with Rozlytrek. These may be symptoms related to QT prolongation.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vision problems.</strong> Rozlytrek may cause vision problems. Your healthcare provider may stop Rozlytrek and refer you to an eye specialist if you develop severe vision problems during treatment with Rozlytrek. Tell your healthcare provider right away if you have any loss of vision or any change in vision, including:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurry vision</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new or increased floaters</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seeing flashes of light</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light hurting your eyes</p><p>&nbsp;</p><p>See &ldquo;What are the possible side effects of ROZLYTREK?&rdquo; for more information about side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>It is not known if Rozlytrek is safe and effective for use in children less than 12 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and </strong><strong>Rozlytrek</strong></p><p><strong>Tell your healthcare provider about all the medicines you take, </strong>including prescription and over-the-counter medicines, vitamins, or herbal supplements.</p><ul><li>Certain other medicines may affect how Rozlytrek works causing side effects. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.&nbsp;</li></ul><p><strong>Taking Rozlytrek with food and drink</strong></p><p>You should not drink grapefruit juice or eat grapefruit during your treatment with Rozlytrek. It may increase the amount of entrectinib in your blood to a harmful level.</p><p>&nbsp;</p><p><strong>Pregnancy and contraception</strong></p><p><strong>Before you take </strong><strong>ROZLYTREK</strong><strong>, tell your healthcare provider if you:</strong></p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or plan to become pregnant. Rozlytrek can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with Rozlytrek or think you may be pregnant.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are able to become pregnant, your healthcare provider will do a pregnancy test before you start treatment with Rozlytrek.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Females who are able to become pregnant should use effective birth control during treatment with ROZLYTREK and for at least 5 weeks after the final dose.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Males who have female partners that are able to become pregnant should use effective birth control during treatment with Rozlytrek and for 3 months after the final dose.</p><p>&nbsp;</p><p><strong>Breast‑feeding</strong></p><p>Before you take Rozlytrek, tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if Rozlytrek passes into your breast milk. Do not breastfeed during treatment with Rozlytrek and for 7 days after the final dose of Rozlytrek. Talk to your healthcare provider about the best way to feed your baby during this time.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Do not drive or operate heavy machinery until you know how ROZLYTREK affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Rozlytrek exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking Rozlytrek unless your healthcare provider tells you to.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Rozlytrek if you develop side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Rozlytrek 1 time each day with or without food.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow whole Rozlytrek capsules. Do not open, crush, chew or dissolve the capsule contents.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you miss a dose of Rozlytrek, take it as soon as you remember. If your next dose is due within 12 hours, skip the missed dose and take your next dose at your regular time.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you vomit right after taking a dose of Rozlytrek, you may take the dose again.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not drink grapefruit juice or eat grapefruit during your treatment with Rozlytrek. It may increase the amount of entrectinib in your blood to a harmful level.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not drive or operate heavy machinery until you know how Rozlytrek affects you. If you experience dizziness, fainting, tiredness, blurred vision, memory loss, changes in mental status, confusion, or hallucinations, do not drive or operate heavy machines until your symptoms resolve.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor, or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Rozlytrek can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Rozlytrek</strong> can cause serious side effects, including:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>See &ldquo;Warning and Precaution?&rdquo;</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The most common side effects of </strong><strong>Rozlytrek</strong> <strong>include:</strong></p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in taste</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;swelling</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal touch sensation</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, mental status changes, memory problems, and hallucinations</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vision changes</p><p>&nbsp;</p><p>For more information, and if you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep Rozlytrek out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the bottle and carton (EXP). The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Do not store above 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is entrectinib (100mg or 200mg per capsule).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inactive ingredients include: tartaric acid, lactose anhydrous, hypromellose, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. Yellow opaque capsule shell contains: hypromellose, titanium dioxide, and yellow iron oxide. Orange opaque capsule shell contains: hypromellose, titanium dioxide, and FD&amp;C Yellow No. 6. Printing ink contains: shellac, propylene glycol, strong ammonia solution, and FD&amp;C Blue No. 2 aluminum lake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -          Rozlytrek capsules are supplied as:

-        100 mg hard capsules: Size 2 yellow opaque, with “ENT 100” printed in blue ink; available in:

o   HDPE bottles of 30 capsules: NDC 50242-091-30.


-        200 mg hard capsules: Size 0 orange opaque, with “ENT 200” printed in blue ink; available in:

o   HDPE bottles of 90 capsules: NDC 50242-094-90.


* Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>F. Hoffmann-La Roche Ltd,</p><p>Grenzacherstrasse 124,</p><p>CH-4070 Basel,</p><p>Switzerland.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised Aug 2019.

To report any side effect(s):
•	Saudi Arabia:
	The National Pharmacovigilance and Drug Safety Centre (NPC)
o	Fax: +966-11-205-7662
o	Call NPC at +966-11-2038222, Exts: 2317-2356-2340.
o	SFDA call center: 19999 
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc

•	Other GCC States:
	Please contact the relevant competent authority.

•	Council of Arab Health Ministers:
This is a Medicament
	Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you. 
	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament. 
	The doctor and the pharmacist are the experts in medicines, their benefits and risks. 
	Do not by yourself interrupt the period of treatment prescribed for you. 
	Do not repeat the same prescription without consulting your doctor. 
	Keep all medicaments out of reach of children. 
Council of Arab Health Ministers
Union of Arab Pharmacists

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - روزليترك هو دواء لعلاج مرض السرطان ، يحتوي على مادة فعالة تُسمى (إنتراكتينيب).</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - روزليترك دواء وصفي، يستخدم من أجل علاج:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين المصابين بسرطان الرئة ذو الخلايا غير الصغيرة والذي انتشر إلى أجزاء أخرى من الجسم وسببه جين ROS1 غير الطبيعي.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغين والأطفال في عمر ۱۲ سنة فأكثر والمصابين بأورام سرطانية صلبة:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التي تسببت فيها بعض جينات التيروزين كيناز التَغْذويّ العصبيّ &nbsp;الغير طبيعية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; والتي انتشرت لأجزاء أخرى من الجسم، أو إذا كانت الجراحة لإزالة السرطان من المحتمل أن تتسبب في مضاعفات شديدة.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يوجد بديل علاجي مرضٍ، أو أن السرطان قد انتشر على الرغم من استخدام علاج آخر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- قبل أن تتعاطى روزليترك</strong>، أخبر مقدم الرعاية الصحية الخاص بك بجميع مشاكلك الصحية، بما في ذلك ما يلي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكبد أو الكلى.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في القلب، بما في ذلك حالة تسمى متلازمة كيو تي الطويلة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الجهاز العصبي.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت&nbsp; تعاني حالياً، أو قد عانيت مسبقاً من مشاكل في العين أو الرؤية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>- المحاذير والاحتياطات:</strong></p><p dir="RTL"><strong>&nbsp; </strong>قد يسبب روزليترك آثاراً جانبية خطيرة، بما في ذلك:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قصور القلب الاحتقاني:</strong></p><p dir="RTL">قد يسبب روزليترك قصور القلب الاحتقاني أو يجعله أسوأ. أخبر مقدم الرعاية الصحية على الفور إذا لاحظت أياً من العلامات والأعراض التالية لفشل القلب الاحتقاني:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال المستمر أو الصفير.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس عند الاستلقاء.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن المفاجئ.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الضيق في التنفس.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب، الضعف، أو الاعياء.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم في الكاحلين، أوالقدمين، أوالساقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التأثيرات على الجهاز العصبي المركزي:</strong></p><p dir="RTL">قد يسبب عقار روزليترك دوخة، أو تغيرات في حالتك المزاجية، أو قد يؤثر على طريقة تفكيرك ويسبب الالتباس والهلوسة ومشاكل في التركيز والإنتباه والذاكرة والنوم. أخبر مقدم الرعاية الصحية على الفور إذا لاحظت أياً من هذه الأعراض.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كسور العظام:</strong></p><p dir="RTL">قد يزيد علاج روزليترك من خطر الإصابة بكسور العظام. قد تحدث كسور في العظام بسبب سقوط أو إصابة أخرى أو دون &nbsp;سبب. أخبر مقدم الرعاية الصحية إذا كنت تعاني من ألم أو تغيرات في الحركة أو تشوهات في العظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مشاكل الكبد (تسمم الكبد):</strong></p><p dir="RTL">سيقوم مقدم الرعاية الصحية بإجراء فحوصات دم للتحقق من وظائف الكبد أثناء العلاج مع روزليترك. أخبر مقدم الرعاية الصحية على الفور <u>إذا كنت تعاني من أعراض مشاكل الكبد بما في ذلك</u>: (فقدان الشهية أو الغثيان أو القيء أو الألم على الجانب الأيمن العلوي من منطقة البطن). قد يتوقف مقدم الرعاية الصحية الخاص بك مؤقتًا عن العلاج أو يخفض الجرعة أو يوقف عقار روزليترك نهائيًا إذا كنت تعاني من مشاكل في الكبد مع تناول روزليترك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>زيادة مستوى حمض اليوريك في الدم (فرط حمض يوريك الدم):</strong></p><p dir="RTL">قد يسبب روزليترك زيادة حمض اليوريك. قد يقوم مقدم الرعاية الصحية الخاص بك بإجراء اختبارات قبل وأثناء علاجك مع روزليترك من أجل التحقق من مستوى حمض اليوريك في دمك. قد يصف لك مزود الرعاية الصحية بعض الأدوية إذا كان لديك مستويات عالية من حمض اليوريك في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تغييرات في النشاط الكهربائي للقلب </strong><strong>)</strong><strong>تسمى إطالة كيو تي أو متلازمة فترة كيو تي طويلة الأمد):</strong></p><p dir="RTL">متلازمة فترة كيو تي طويلة الأمد من الممكن أن تسبب&nbsp; عدم انتظام في نبضات القلب والتي من الممكن&nbsp; أن تشكل خطراً على الحياة. سيقوم مقدم الرعاية الصحية بإجراء اختبارات قبل وأثناء علاجك مع روزليترك من أجل التحقق من النشاط الكهربائي لقلبك وأملاح جسمك (الكهارل أو الإلكتروليت). أخبر مقدم الرعاية الصحية على الفور إذا كنت تشعر بالإغماء، أو بالدوار، أو بالدوخة، أو تشعر بأن قلبك ينبض بشكل غير منتظم أو سريع أثناء علاجك مع روزليترك. قد تكون هذه الأعراض مرتبطة بمتلازمة فترة كيو تي طويلة الأمد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مشاكل في الرؤية:</strong></p><p dir="RTL">قد يسبب علاج روزليترك مشاكل في الرؤية. قد يقوم مقدم الرعاية الصحية الخاص بك بإيقاف علاج روزليترك ويحيلك إلى أخصائي العيون إذا كنت تعاني من مشاكل حادة في الرؤية أثناء العلاج مع روزليترك. أخبر مقدم الرعاية الصحية على الفور إذا تعرضت لفقدان الرؤية أو أي تغيير في الرؤية، <u>بما في ذلك</u>:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواجية في الرؤية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرؤية الضبابية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور عوائم العين (الأجسام الطافية أو الأجسام العائمة) -&nbsp; بدء ظهورها أو تزايدها-.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية ومضات الضوء.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية العين للضوء (أن يضر الضوء عينيك).</p><p dir="RTL">لمزيد من المعلومات حول الآثار الجانبية، انظر الجزء الرابع من هذه النشرة &quot;ما هي الآثار الجانبية المحتملة لـعلاج روزليترك؟&quot;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>- الأطفال والمراهقين</u></strong><strong>: </strong></p><p dir="RTL">من غير المعروف ما إذا كان استخدام علاج روزليترك آمن وفعال للأطفال الذين تقل أعمارهم عن ۱۲ عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>- أدوية أخرى وعقار روزليترك: </u></strong></p><p dir="RTL">أطلع مقدم الرعاية الصحية الخاص بك على جميع الأدوية التي تتعاطاها، بما في ذلك الأدوية الوصفية، أو الأدوية التي تؤخذ دون وصفة طبية، أو الفيتامينات، أو المكملات العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض الأدوية الأخرى قد تؤثر على كيفية عمل علاج روزليترك مما يتسبب في ظهور بعض الآثار الجانبية. كن على علم وإحاطة جيدين بالأدوية التي تتناولها واحتفظ بقائمة منها لتطلع مزود الرعاية الصحية والصيدلي عليها عندما تحصل على دواء جديد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>- تناول</u></strong><strong><u> </u></strong><strong><u>وعقار روزليترك مع الطعام والشراب</u></strong><strong>: </strong></p><p dir="RTL">يجب ألا تشرب عصير أو أن تأكل الجريب فروت خلال فترة العلاج بعقار روزليترك. حيث من الممكن أن يزيد من كمية إنتراكتينيب في دمك إلى مستوى ضار.</p><p dir="RTL">- <strong><u>الحمل ووسائل منع الحمل</u>: </strong></p><p dir="RTL">قبل أن تتناولي علاج روزليترك، أخبري مقدم الرعاية الصحية إذا كنتِ:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاملاً أو تخططين للحمل حيث أنه من الممكن لعلاج روزليترك أن يضر طفلك الذي لم يولد بعد. أخبري مقدم الرعاية الصحية على الفور إذا كنتِ حاملاً أثناء فترة العلاج مع عقار روزليترك أو إذا كنتِ تعتقدين بأنك حامل.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قادرةً على الحمل، فسيقوم مقدم الرعاية الصحية الخاص بكِ بإجراء اختبار الحمل قبل بدء العلاج مع عقار روزليترك.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تستخدم الإناث القادرات على الحمل وسيلة فعالة لمنع الحمل أثناء العلاج بعقار روزليترك ولمدة ٥ أسابيع على الأقل بعد الجرعة النهائية.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يستخدم الذكور الذين لدى شريكاتهم الإناث القدرة على الإنجاب وسائل منع حمل فعالة أثناء العلاج مع عقار روزليترك ولمدة ۳ أشهر بعد الجرعة النهائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>- الرضاعة الطبيعية</u></strong><strong>: </strong></p><p dir="RTL">&nbsp;قبل أن تبدئي استخدام عقار روزليترك، أخبري مقدم الرعاية الصحية إذا كنتِ ترضعين أو تخططين لإرضاع طفلك رضاعة طبيعية. ليس معروفًا ما إذا كان روزليترك ينتقل إلى حليب الثدي. لا ترضعي خلال فترة العلاج بروزليترك ولمدة ۷ أيام بعد الجرعة النهائية. تحدثي إلى مقدم الرعاية الصحية الخاص بكِ حول أفضل طريقة لإطعام طفلك خلال هذا الوقت.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong><u>- القيادة واستخدام الآلات</u></strong><strong>: </strong></p><p dir="RTL">لا تقم بقيادة السيارة أو تشغيل الآلات الثقيلة حتى تعرف مدى تأثير علاج روزليترك عليك. إذا أصبت بالدوخة أو الإغماء أو التعب أو عدم وضوح الرؤية أو فقدان الذاكرة أو تغيرات في الحالة العقلية أو الارتباك أو الهلوسة، فلا تقد السيارة أو تقوم بتشغيل الآلات الثقيلة حتى تزول الأعراض. <strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>تناول روزليترك بالطريقة التي أطلعك عليها مقدم الرعاية الصحية الخاص بك. لا تغير الجرعة الخاصة بك أو تتوقف عن تناوله إلا إذا أخبرك موفر الرعاية الصحية بذلك.</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>قد يقوم موفر الرعاية الصحية الخاص بك بتغييرالجرعة، أو إيقاف علاج روزليترك مؤقتًا، أو بشكلٍ دائم إذا ظهرت لديك آثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>تناول روزليترك مرة واحدة كل يوم مع الطعام أو بدونه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>ابتلع كبسولة روزليترك كاملة. لا تفتح أو تسحق أو تمضغ أو تذوب محتويات الكبسولة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>إذا نسيت تناول جرعة من روزليترك، خذها بمجرد أن تتذكر. إذا كانت موعد تناول الجرعة التالية يحين في غضون ۱۲ ساعة، فتجاوز الجرعة الفائتة وتناول الجرعة التالية في وقتك المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>إذا تقيأت مباشرة بعد تناول جرعة من روزليترك، فيمكنك أخذ جرعة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>يجب ألا تشرب عصير الجريب فروت أو أن تأكل الجريب فروت خلال فترة العلاج بروزليترك حيث قد يعمل على زيادة كمية المادة الفعالى إنتراكتينيب في دمك إلى مستوى ضار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>لا تقد السيارة أو تقوم بتشغيل الآلات الثقيلة حتى تعرف مدى تأثرك بروزليترك. إذا أحسست بدوخة أو إغماء أو تعب أو عدم وضوح الرؤية أو فقدان الذاكرة أو أحسست بتغيرات في الحالة العقلية أو ارتباك أو هلوسة، فلا تقد السيارة أو تشغل الآلات الثقيلة حتى تزول تلك الأعراض.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى حول استخدام هذا الدواء ، يمكنك طرحها على طبيبك الخاص أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يسبب روزليترك آثارًا جانبية، إلا أنها قد لا تصيب الجميع.</p><p>يمكن أن يسبب روزليترك آثارًا جانبية خطيرة، بما في ذلك:</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong><strong>انظر &quot;التحذير والاحتياطات&quot;.</strong></p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong><strong>الآثار الجانبية الأكثر شيوعا من روزليترك تشمل ما يلي:</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير المذاق</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في الاحساس عند اللمس</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإرتباك وتغيير الحالة العقلية ومشاكل في الذاكرة والهلوسة</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الرؤية</p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت تعاني من أي آثار جانبية قم بالتحدث إلى طبيبك أو ممرضتك. يشمل ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. عن طريق الإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>احتفظ بروزليترك بعيدًا عن مرأى و تناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والكرتون (EXP). يشير تاريخ انتهاء الصلاحية هذا إلى آخر يوم من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>لا تخزنه في درجة حرارة أعلى من ۳۰ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>لا يجب التخلص من الأدوية عبر مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد في حاجة إليها، حيث تساعد هذه الإجراءات في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>المادة الفعالة هي إنتراكتينيب (۱۰۰ ملغم أو ۲۰۰ ملغم لكل كبسولة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>تشمل المكونات غير الفعالة على حمض الترتريك، ولاكتوز لا مائي، وهايبروميلوز، وكروسبوفيدون، وسليولوز دقيق التبلور، وثاني أكسيد السيليكون الغروي، وستيرات المغنيسيوم. تحتوي قشرة الكبسولة الصفراء غير الشفافة على هيبوميلوز، وثاني أكسيد التيتانيوم، وأكسيد الحديد الأصفر. تحتوي قشرة الكبسولة البرتقالية على هيبوميلوز، وثاني أكسيد التيتانيوم، ومادة الغذاء والدواء ومستحضرات التجميل (FD&amp;C) الأصفر رقم ٦. يحتوي حبر الطباعة على اللك، والبروبيلين غليكول، ومحلول الأمونيا القوي، ومادة الغذاء والدواء ومستحضرات التجميل (FD&amp;C) الأزرق رقم ۲ وصبغ الألمنيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp; </strong>تتوفر كبسولات روزليترك على النحو التالي:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولات صلبة ۱۰۰ ملغم: حجم ۲ أصفر معتم، بعبوة مطبوعة بالحبر الأزرق لاحتواء كبسولات ۱۰۰ ملغم ومتوفره على النحو التالي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زجاجات بولي ايثيلين عالي الكثافة تحتوي على ۳۰ كبسولة: NDC 50242-091-30.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولات صلبة ۲۰۰ ملغم: حجم ۰ برتقالي معتم، بعبوة مطبوعة بالحبر الأزرق لاحتواء كبسولات ۲۰۰ ملغم ومتوفر على النحو التالي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زجاجات بولي ايثيلين عالي الكثافة تحتوي على ٩۰ كبسولة: NDC 50242-094-90.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>v&nbsp; </em></strong><em>قد لا يمكن تسويق جميع أحجام العبوات.</em></p><p dir="RTL"><em>&nbsp;</em></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة ف. هوفمان-لا روش المحدودة،</p><p>جرينزاتشيرستراس 124،</p><p>سي إتش &ndash; 4070 بازل،</p><p>سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في أغسطس ۲۰۱٩م.

للإبلاغ عن الآثار الجانبية:
o	المملكة العربية السعودية:
-	المركز الوطني للتيقظ والسلامة الدوائية
o	فاكس: 7662-205-11-966+
o	او اتصل بالمركز على رقم 2038222-11-966+ تحويلة: 2340-2356-2317
o	مركز الاتصال الموحد 19999 
o	بريد الكتروني: npc.drug@sfda.gov.sa
o	الموقع الإلكتروني: www.sfda.gov.sa

o	دول مجلس التعاون الخليجي الأخرى:
-	يرجى التواصل مع الهيئة المعنية ذات الصلة.


هذا المنتج دوائي
-	قد تؤثر المنتجات الدوائية على صحتك، ويعد استهلاكه بخلاف الطريقة المحددة أمرًا خطيرًا.
-	اتبع وصفة الطبيب وطريقة الاستخدام وتعليمات الصيدلي الذي باع لك هذا الدواء بدقة.
-	الطبيب والصيدلي خبراء في المنتجات الدوائية وفوائدها ومخاطرها.
-	لا تقطع فترة العلاج المحددة لك من تلقاء نفسك.
-	لا تكرر استخدام نفس الوصفة الطبية دون استشارة طبيبك.
-	احتفظ بجميع المنتجات الدوائية بعيدًا عن متناول الأطفال.


	مجلس وزارات الصحة العربية
اتحاد الصيادلة العرب

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROZLYTREK 100 mg Hard capsules.
ROZLYTREK 200 mg Hard capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Entrectinib is a kinase inhibitor. The molecular formula for entrectinib is C31H34F2N6O2 and the molecular weight is 560.64 Daltons. The chemical name is N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide. 

Entrectinib is white to pale pink powder.
ROZLYTREK (entrectinib) capsules for oral use are supplied as printed hard-shell capsules containing 100 mg (yellow opaque HPMC capsule) or 200 mg of entrectinib (orange opaque HPMC capsule). Inactive ingredients are tartaric acid, lactose anhydrous, hypromellose, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.
The yellow opaque capsule shell contains hypromellose, titanium dioxide, and yellow iron oxide. The orange opaque capsule shell contains hypromellose, titanium dioxide, and FD&C yellow #6. The printing ink contains shellac, propylene glycol, strong ammonia solution, and FD&C blue #2 aluminum lake.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsules:
•	100 mg: Size 2 yellow opaque body and cap, with “ENT 100” printed in blue ink on body. 
•	200 mg: Size 0 orange opaque body and cap, with “ENT 200” printed in blue ink on body.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>ROS1</em>-Positive Non-Small Cell Lung Cancer</strong></p><p>ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are <em>ROS1</em>-positive.</p><p>&nbsp;</p><p><strong><em>NTRK</em> Gene Fusion-Positive Solid Tumors</strong></p><p>ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a neurotrophic tyrosine receptor kinase (<em>NTRK</em>) gene fusion without a known acquired resistance mutation,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are metastatic or where surgical resection is likely to result in severe morbidity, and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have either progressed following treatment or have no satisfactory alternative therapy.</p><p>This indication is approved under accelerated approval based on tumor response rate and durability of response <em>[</em><em>see </em><em>Pharmacodynamic properties, Clinical efficacy and safety (5.1)]</em>. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Patient Selection</strong></p><p>Select patients for the treatment of metastatic NSCLC with ROZLYTREK based on the presence of <em>ROS1</em> rearrangement(s) in tumor specimens <em>[</em><em>see </em><em>Pharmacodynamic properties, Clinical efficacy and safety (5.1)]</em>. An FDA-approved test for detection of <em>ROS1</em> rearrangement(s) in NSCLC for selecting patients for treatment with ROZLYTREK is not available.</p><p>Select patients for treatment of locally advanced or metastatic solid tumors with ROZLYTREK based on the presence of a <em>NTRK</em> gene fusion <em>[</em><em>see </em><em>Pharmacodynamic properties, Clinical efficacy and safety (5.1)]</em>. An FDA-approved test for the detection of <em>NTRK</em> gene fusion in solid tumors is not available.</p><p>&nbsp;</p><p><strong>Recommended Dosage for <em>ROS1</em>-Positive Non-Small Cell Lung Cancer</strong></p><p>The recommended dosage of ROZLYTREK is 600 mg orally once daily with or without food until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p><strong>Recommended Dosage for <em>NTRK </em>Gene Fusion-Positive Solid Tumors</strong></p><p><u>Adults</u></p><p>The recommended dosage of ROZLYTREK in adults is 600 mg orally once daily with or without food until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p><u>Pediatric Patients 12 Years and Older (Adolescents)</u></p><p>The recommended dosage of ROZLYTREK is based on body surface area (BSA) as shown in Table 1 below. Take ROZLYTREK orally once daily with or without food until disease progression or unacceptable toxicity.</p><p><strong>Table 1: Dosing in Pediatric Patients 12 Years and Older (Adolescents)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Body Surface Area (BSA)</strong></p></td><td><p><strong>Recommended Dosage</strong></p><p><strong>(Orally once daily)</strong></p></td></tr><tr><td><p>Greater than 1.50 m<sup>2</sup></p></td><td><p>600 mg</p></td></tr><tr><td><p>1.11 to 1.50 m<sup>2</sup></p></td><td><p>500 mg</p></td></tr><tr><td><p>0.91 to 1.10 m<sup>2</sup></p></td><td><p>400 mg</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Dosage Modifications for Adverse Reactions</strong></p><p>The recommended dosage reductions for adverse reactions are provided in Table 2.</p><p><strong>Table 2: Recommended Dose Reductions for ROZLYTREK Adverse Reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Action</strong></p></td><td><p><strong>Adults and Pediatric Patients 12 Years and Older with BSA Greater than 1.50 m<sup>2</sup></strong></p><p><strong>(Orally once daily)</strong></p></td><td><p><strong>Pediatric Patients 12 Years and Older with BSA of 1.11 to 1.50 m<sup>2</sup></strong></p><p><strong>(Orally once daily)</strong></p></td><td><p><strong>Pediatric Patients 12 Years and Older with BSA of 0.91 to 1.10 m<sup>2</sup></strong></p><p><strong>(Orally once daily)</strong></p></td></tr><tr><td><p>First dose reduction</p></td><td><p>400 mg</p></td><td><p>400 mg</p></td><td><p>300 mg</p></td></tr><tr><td><p>Second dose reduction*</p></td><td><p>200 mg</p></td><td><p>200 mg</p></td><td><p>200 mg</p></td></tr></tbody></table><p>*For a subsequent modification, permanently discontinue ROZLYTREK in patients who are unable to tolerate ROZLYTREK after two dose reductions.</p><p>Table 3 describes dosage modifications for specific adverse reactions.</p><p><strong>Table 3: Recommended Dosage Modifications for ROZLYTREK for Adverse Reactions</strong><em> </em></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Adverse Reaction </strong></p></td><td style="vertical-align:top"><p><strong>Severity* </strong></p></td><td style="vertical-align:top"><p><strong>Dosage Modification </strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Congestive Heart Failure</p><p><em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p></td><td style="vertical-align:top"><p>Grade 2 or 3</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until recovered to less than or equal to Grade 1.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at reduced dose.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue ROZLYTREK.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Central Nervous System Effects</p><p><em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p></td><td style="vertical-align:top"><p>Intolerable<br />Grade 2</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at same dose or reduced dose, as clinically appropriate.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at reduced dose.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue ROZLYTREK.&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatotoxicity</p><p><em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p></td><td style="vertical-align:top"><p>Grade 3</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at same&nbsp; dose if resolution occurs within 4 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue if adverse reaction does not resolve within 4 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 4</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until recovery to less than or equal to Grade 1 or to baseline.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at&nbsp; reduced dose if resolution occurs within 4 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue if adverse reaction does not resolve within 4 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue for recurrent Grade 4 events.</p></td></tr><tr><td style="vertical-align:top"><p>ALT or AST greater than 3 times ULN with concurrent total bilirubin greater than 1.5 times ULN (in the absence of cholestasis or hemolysis).</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue ROZLYTREK.</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricemia</p><p><em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p></td><td style="vertical-align:top"><p>Symptomatic</p><p>&nbsp;or</p><p>Grade 4</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Initiate urate-lowering medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until improvement of signs or symptoms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume ROZLYTREK at same or reduced dose.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>QT Interval Prolongation</p><p><em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p></td><td style="vertical-align:top"><p>QTc greater than 500 ms</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until QTc interval recovers to baseline.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at same dose if factors that cause QT prolongation are identified and corrected.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at reduced dose if other factors that cause QT prolongation are <u>not</u> identified.</p></td></tr><tr><td style="vertical-align:top"><p>Torsade de pointes; polymorphic ventricular tachycardia; signs/symptoms of serious arrhythmia</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue ROZLYTREK.</p></td></tr><tr><td style="vertical-align:top"><p>Vision Disorders <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p></td><td style="vertical-align:top"><p>Grade 2 or above</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until improvement or stabilization.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at same dose or reduced dose, as clinically appropriate.</p></td></tr><tr><td style="vertical-align:top"><p>Anemia or Neutropenia <em>[</em><em>see Undesirable effects (4.8)</em><em>]</em></p></td><td style="vertical-align:top"><p>Grade 3 or 4</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until recovery to less than or equal to Grade 2.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at the same dose or reduced dose, as clinically appropriate.</p></td></tr><tr><td style="vertical-align:top"><p>Other Clinically Relevant Adverse Reactions</p></td><td style="vertical-align:top"><p>Grade 3 or 4</p></td><td style="vertical-align:top"><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold ROZLYTREK until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume at the same or reduced dose, if resolution occurs within 4 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue if adverse reaction does not resolve within 4 weeks.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue for recurrent Grade 4 events.</p></td></tr></tbody></table><p><sup>*</sup>Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Dosage Modifications for Drug Interactions</strong></p><p><u>Moderate and Strong CYP3A Inhibitors</u></p><p><em>Adults and Pediatric Patients 12 Years and Older with BSA Greater than 1.50 m<sup>2</sup> </em><em>&nbsp;</em></p><p>Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors. If coadministration cannot be avoided, reduce the ROZLYTREK dose as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Moderate CYP3A Inhibitors</em>: 200 mg orally once daily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Strong CYP3A Inhibitors</em>: 100 mg orally once daily</p><p>After discontinuation of a strong or moderate CYP3A inhibitor for 3 to 5 elimination half-lives, resume the ROZLYTREK dose that was taken prior to initiating the CYP3A inhibitor <em>[</em><em>see Interaction with other medicinal products and other forms of interaction (</em><em>4.5), </em><em>Pharmacodynamic Properties (5.1)</em><em>]. </em></p><p><em>&nbsp;</em></p><p><strong>Administration</strong></p><p>Swallow capsules whole. Do not open, crush, chew, or dissolve the contents of the capsule.</p><p>If a patient misses a dose, instruct patients to make up that dose unless the next dose is due within 12 hours.</p><p>If a patient vomits immediately after taking a dose, instruct patients to repeat that dose. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Congestive Heart Failure</strong></p><p>Among the 355 patients who received ROZLYTREK across clinical trials, congestive heart failure (CHF) occurred in 3.4% of patients, including Grade 3 (2.3%) <em>[see Undesirable effects (4.8)</em><em>]. </em>In clinical trials, baseline cardiac function and routine cardiac monitoring other than electrocardiograms (ECGs) were not conducted and eligibility criteria excluded patients with symptomatic CHF, myocardial infarction, unstable angina, and coronary artery bypass graft within 3 months of study entry. Among the 12 patients with CHF, the median time to onset was 2 months (range: 11 days to 12 months). ROZLYTREK was interrupted in 6 of these patients (50%) and discontinued in 2 of these patients (17%). CHF resolved in 6 patients (50%) following interruption or discontinuation of ROZLYTREK and institution of appropriate medical management. In addition, myocarditis in the absence of CHF was documented in 0.3% of patients.</p><p>Assess left ventricular ejection fraction (LVEF) prior to initiation of ROZLYTREK in patients with symptoms or known risk factors for CHF. Monitor patients for clinical signs and symptoms of CHF, including shortness of breath and edema. For patients with myocarditis, with or without a decreased ejection fraction, MRI or cardiac biopsy may be required to make the diagnosis. For patients with new onset or worsening CHF, withhold ROZLYTREK, institute appropriate medical management, and reassess LVEF. Based on the severity of CHF or worsening LVEF, resume ROZLYTREK at a reduced dose upon recovery to baseline or permanently discontinue <em>[see </em><em>Posology and method of administration</em><em> (4.2)]</em>.</p><p>&nbsp;</p><p><strong>Central Nervous System Effects</strong></p><p>A broad spectrum of central nervous system (CNS) adverse reactions occurred in patients receiving ROZLYTREK, including cognitive impairment, mood disorders, dizziness, and sleep disturbances.</p><p>Among the 355 patients who received ROZLYTREK across clinical trials, 96 (27%) experienced cognitive impairment; symptoms occurred within 3 months of starting ROZLYTREK in 74 (77%). Cognitive impairment included cognitive disorders (8%), confusional state (7%), disturbance in attention (4.8%), memory impairment (3.7%), amnesia (2.5%), aphasia (2.3%), mental status changes (2%), hallucinations (1.1%), and delirium (0.8%). Grade 3 cognitive adverse reactions occurred in 4.5% of patients. Among the 96 patients with cognitive impairment, 13% required a dose reduction, 18% required dose interruption and 1% discontinued ROZLYTREK due to cognitive adverse reactions.</p><p>Among the 355 patients who received ROZLYTREK across clinical trials, 36 (10%) experienced mood disorders. The median time to onset of mood disorders was 1 month (range: 1 day to 9 months). Mood disorders occurring in &sup3; 1% of patients included anxiety (4.8%), depression (2.8%) and agitation (2%). Grade 3 mood disorders occurred in 0.6% of patients. One completed suicide was reported 11 days after treatment had ended. Among the 36 patients who experienced mood disorders, 6% required a dose reduction, 6% required dose interruption and no patients discontinued ROZLYTREK due to mood disorders.</p><p>Dizziness occurred in 136 (38%) of the 355 patients. Among the 136 patients who experienced dizziness, Grade 3 dizziness occurred in 2.2% of patients. Ten percent of patients required a dose reduction, 7% required dose interruption and 0.7% discontinued ROZLYTREK due to dizziness.</p><p>Among the 355 patients who received ROZLYTREK across clinical trials, 51 (14%) experienced sleep disturbances. Sleep disturbances included insomnia (7%), somnolence (7%), hypersomnia (1.1%), and sleep disorder (0.3%). Grade 3 sleep disturbances occurred in 0.6% of patients. Among the 51 patients who experienced sleep disturbances, 6% required a dose reduction and no patients discontinued ROZLYTREK due to sleep disturbances.</p><p>The incidence of CNS adverse reactions was similar in patients with and without CNS metastases; however, the incidence of dizziness (38% vs 31%), headache (21% vs 13%), paresthesia (20% vs 6%), balance disorder (13% vs 4%), and confusional state (11% vs 2%) appeared to be increased in patients with CNS metastases who had received prior CNS irradiation (N = 90) compared to those who did not (N = 48).</p><p>Advise patients and caregivers of these risks with ROZLYTREK. Advise patients not to drive or operate hazardous machinery if they are experiencing CNS adverse reactions. Withhold and then resume at same or reduced dose upon improvement, or permanently discontinue ROZLYTREK based on severity <em>[see Posology and method of administration</em><em> (4.2)</em><em>]</em>.</p><p>&nbsp;</p><p><strong>Skeletal Fractures</strong></p><p>ROZLYTREK increases the risk of fractures. In an expanded safety population that included 338 adult patients and 30 pediatric patients who received ROZLYTREK across clinical trials, 5% of adult patients and 23% of pediatric patients experienced fractures <em>[see </em><em>Fertility, pregnancy and lactation (4.6)</em><em>]</em>. In adult patients, some fractures occurred in the setting of a fall or other trauma to the affected area, while in pediatric patients all fractures occurred in patients with minimal or no trauma. In general, there was inadequate assessment for tumor involvement at the site of fracture; however, radiologic abnormalities possibly indicative of tumor involvement were reported in some patients. In both adult and pediatric patients, most fractures were hip or other lower extremity fractures (e.g., femoral or tibial shaft). In a limited number of patients, bilateral femoral neck fractures occurred. The median time to fracture was 3.8 months (range 0.3 to 18.5 months) in adults and 4.0 months (range: 1.8 months to 7.4 months) in pediatric patients. ROZLYTREK was interrupted in 41% of adults and 43% of pediatric patients due to fractures. No patients discontinued ROZLYTREK due to fractures.</p><p>Promptly evaluate patients with signs or symptoms (e.g., pain, changes in mobility, deformity) of fractures. There are no data on the effects of ROZLYTREK on healing of known fractures and risk of future fractures.</p><p>&nbsp;</p><p><strong>Hepatotoxicity</strong></p><p>Among the 355 patients who received ROZLYTREK, increased AST of any grade occurred in 42% of patients and increased ALT of any grade occurred in 36%. Grade 3 &ndash; 4 increased AST or ALT occurred in 2.5% and 2.8% of patients, respectively; the incidence may be underestimated as 4.5% of patients had no post-treatment liver function tests <em>[</em><em>see</em><em> Undesirable effects (4.8)</em><em>]</em>. The median time to onset of increased AST was 2 weeks (range: 1 day to 29.5 months). The median time to onset of increased ALT was 2 weeks (range: 1 day to 9.2 months). Increased AST or ALT leading to dose interruptions or reductions occurred in 0.8% and 0.8% of patients, respectively. ROZLYTREK was discontinued due to increased AST or ALT in 0.8% patients.</p><p>Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Withhold or permanently discontinue ROZLYTREK based on the severity. If withheld, resume ROZLYTREK at the same or reduced dose <em>[see </em><em>Posology and method of administration</em><em> (4.2)</em><em>]</em>.</p><p>&nbsp;</p><p><strong>Hyperuricemia</strong></p><p>Among 355 patients who received ROZLYTREK across clinical trials, 32 patients (9%) experienced hyperuricemia reported as adverse reactions with symptoms, as well as elevated uric acid levels. Grade 4 hyperuricemia occurred in 1.7% of patients, including one patient who died due to tumor lysis syndrome.Among the 32 patients with hyperuricemic adverse reactions, 34% required&nbsp;urate-lowering medication to reduce uric acid levels, 6% required dose reduction and 6% required dose interruption. Hyperuricemia resolved in 73% of patients following initiation of urate-lowering medication without interruption or dose reduction of ROZLYTREK. No patients discontinued ROZLYTREK due to hyperuricemia.</p><p>Assess serum uric acid levels prior to initiating ROZLYTREK and periodically during treatment. Monitor patients for signs and symptoms of hyperuricemia. Initiate treatment with urate-lowering medications as clinically indicated and withhold ROZLYTREK for signs and symptoms of hyperuricemia. Resume ROZLYTREK at same or reduced dose upon improvement of signs or symptoms based on severity<em> [see Posology and method of administration</em><em> (4.2)</em><em>]</em>.</p><p>&nbsp;</p><p><strong>QT Interval Prolongation</strong></p><p>Among the 355 patients who received ROZLYTREK across the clinical trials, 3.1% of patients with at least one post-baseline ECG assessment experienced QTcF interval prolongation of &gt; 60 ms after starting ROZLYTREK and 0.6% had a QTcF interval &gt; 500 ms <em>[</em><em>see</em><em> Undesirable effects (4.8)</em><em>, </em><em>Pharmacodynamic Properties (5.1)</em><em>].</em></p><p>Monitor patients who already have or who are at significant risk of developing QTc interval prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Assess QT interval and electrolytes at baseline and periodically during treatment, adjusting frequency based upon risk factors such as congestive heart failure, electrolyte abnormalities, or concomitant medications known to prolong the QTc interval. Based on the severity of QTc interval prolongation, withhold ROZLYTREK and then resume at same or reduced dose, or permanently discontinue <em>[see </em><em>Posology and method of administration</em><em> (4.2)]</em>.</p><p>&nbsp;</p><p><strong>Vision Disorders</strong></p><p>Among the 355 patients who received ROZLYTREK across clinical trials, vision changes occurred in 21% of patients, including Grade 1 (17%), Grade 2 (2.8%) and Grade 3 (0.8%) <em>[</em><em>see Undesirable effects (4.8)</em><em>]</em>. Vision disorders occurring in &sup3; 1% included blurred vision (9%), photophobia (5%), diplopia (3.1%), visual impairment (2%), photopsia (1.1%), cataract (1.1%), and vitreous floaters (1.1%).&nbsp;</p><p>For patients with new visual changes or changes that interfere with activities of daily living, withhold ROZLYTREK until improvement or stabilization and conduct an ophthalmological evaluation as clinically appropriate. Upon improvement or stabilization, resume ROZLYTREK at same or reduced dose <em>[</em><em>see </em><em>Posology and method of administration</em><em> (4.2)]</em>.</p><p>&nbsp;</p><p><strong>Embryo-Fetal Toxicity</strong></p><p>Based on literature reports in humans with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action, ROZLYTREK can cause fetal harm when administered to a pregnant woman. Administration of entrectinib to pregnant rats resulted in malformations at exposures approximately 2.7 times the human exposure at the 600 mg dose based on area under the curve (AUC).</p><p>Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 5 weeks following the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 3 months after the final dose <em>[</em><em>see </em><em>Fertility, pregnancy and lactation (4.6)</em><em>]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effect of Other Drugs on ROZLYTREK</strong></p><p><u>Moderate and Strong CYP3A Inhibitors</u></p><p><em>Adults and </em><em>Pediatric Patients 12 Years and Older with BSA Greater than 1.50 m<sup>2</sup></em></p><p>Coadministration of ROZLYTREK with a strong or moderate CYP3A inhibitor increases entrectinib plasma concentrations <em>[see Pharmacodynamic Properties (5.1)</em><em>], </em>which could increase the frequency or severity of adverse reactions. Avoid coadministration of strong or moderate CYP3A inhibitors with ROZLYTREK. If coadministration is unavoidable, reduce the ROZLYTREK dose <em>[</em><em>see </em><em>Posology and method of administration (4.2),</em><em> </em><em>Pharmacodynamic Properties (5.1)</em><em>].</em></p><p><em>&nbsp;</em></p><p><em>Pediatric Patients 12 Years and Older with BSA Less Than or Equal to 1.50 m<sup>2</sup></em></p><p>Avoid coadministration of ROZLYTREK with moderate or strong CYP3A inhibitors <em>[see </em><em>Pharmacodynamic Properties (5.1)</em><em>]</em>.<em><sup> </sup></em></p><p>Avoid grapefruit products during treatment with ROZLYTREK, as they contain inhibitors of CYP3A.</p><p><u>&nbsp;</u></p><p><u>Moderate and Strong CYP3A Inducers</u></p><p>Coadministration of ROZLYTREK with a strong or moderate CYP3A inducer decreases entrectinib plasma concentrations <em>[see </em><em>Pharmacodynamic Properties (5.1)</em><em>],</em> which may reduce ROZLYTREK efficacy. Avoid coadministration of strong and moderate CYP3A inducers with ROZLYTREK<em>. </em></p><p>&nbsp;</p><p><strong>Drugs That Prolong QT Interval</strong><u> </u></p><p>QTc interval prolongation can occur with ROZLYTREK. Avoid coadministration of ROZLYTREK with other products with a known potential to prolong QT/QTc interval <em>[see </em><em>Special warnings and precautions for use (4.4), Pharmacodynamic Properties (5.1)]</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p><u>R</u><u>isk Summary<strong> </strong></u></p><p>Based on literature reports in humans with congenital mutations leading to changes in TRK signaling, findings from animal studies, and its mechanism of action <em>[see Pharmacodynamic Properties (5.1)]</em>, ROZLYTREK can cause fetal harm when administered to a pregnant woman. There are no available data on ROZLYTREK use in pregnant women. Administration of entrectinib to pregnant rats during the period of organogenesis resulted in malformations at maternal exposures approximately 2.7 times the human exposure at the 600 mg dose <em>(</em><em>see Data)</em>. Advise pregnant women of the potential risk to a fetus.</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</p><p><u>Data</u></p><p><em>Human Data</em></p><p>Published reports of individuals with congenital mutations in TRK pathway proteins suggest that decreases in TRK-mediated signaling are correlated with obesity, developmental delays, cognitive impairment, insensitivity to pain, and anhidrosis.</p><p><em>Animal Data</em></p><p>Entrectinib administration to pregnant rats during the period of organogenesis at a dose of 200 mg/kg [resulting in exposures up to 2.7 times the human exposure (AUC) at the 600 mg dose] resulted in maternal toxicity and fetal malformations including body closure defects (omphalocele and gastroschisis) and malformations of the vertebrae, ribs, and limbs (micromelia and adactyly), but not embryolethality. Lower fetal weights and reduced skeletal ossification occurred at doses &ge; 12.5 and 50 mg/kg [approximately 0.2 and 0.9 times the human exposure (AUC) at the 600 mg dose], respectively. &nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p><u>Risk Summary</u><strong> </strong></p><p>There are no data on the presence of entrectinib or its metabolites in human milk or their effects on either the breastfed child or on milk production. Because of the potential adverse reactions in breastfed children from ROZLYTREK, advise a lactating woman to discontinue breastfeeding during treatment with ROZLYTREK and for 7 days after the final dose.</p><p>&nbsp;</p><p><strong>Females and Males of Reproductive Potential</strong></p><p><u>Pregnancy Testing</u></p><p>Verify the pregnancy status of females of reproductive potential prior to initiating ROZLYTREK <em>[see </em><em>Fertility, pregnancy and lactation</em><em> (4.6)]</em>.</p><p>&nbsp;</p><p><u>Contraception</u></p><p>ROZLYTREK can cause embryo-fetal harm when administered to a pregnant woman <em>[see </em><em>Fertility, pregnancy and lactation</em><em> (4.6)</em><em>].</em></p><p><em>&nbsp;</em></p><p><em>Females</em></p><p>Advise female patients of reproductive potential to use effective contraception during treatment with ROZLYTREK and for at least 5 weeks following the final dose <em>[see </em><em>Fertility, pregnancy and lactation</em><em> (4.6)</em><em>]</em>.</p><p><em>&nbsp;</em></p><p><em>Males </em></p><p>Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ROZLYTREK and for 3 months following the final dose <em>[see Preclinical safety data</em><em> (5.3)].</em></p><p><em>&nbsp;</em></p><p><strong>Pediatric Use</strong></p><p>The safety and effectiveness of ROZLYTREK in pediatric patients aged 12 years and older with solid tumors that have an <em>NTRK </em>gene fusion have been established. The effectiveness of ROZLYTREK in adolescent patients was established based on extrapolation of data from three open-label, single-arm clinical trials in adult patients with solid tumors harboring an <em>NTRK</em> gene fusion (ALKA, STARTRK-1, and STARTRK-2) and pharmacokinetic data in adolescents enrolled in STARTRK-NG. ROZLYTREK doses based on body surface area in pediatric patients 12 years and older resulted in similar systemic exposure compared to that in adults who received a ROZLYTREK dose of 600 mg <em>[see Posology and method of administration (4.2), Adverse Reactions (4.8), Pharmacodynamic properties, Clinical efficacy and safety</em><em> (5.1), </em><em>Pharmacokinetics properties</em><em> </em><em>(5</em><em>.2)]</em>.</p><p>There is limited clinical experience with ROZLYTREK in pediatric patients. The safety of ROZLYTREK in pediatric patients 12 years of age and older was established based on extrapolation of data in adults and data from 30 pediatric patients enrolled in STARTRK-NG. Of these 30 patients, 7% were &lt; 2 years (n = 2), 77% were 2 to &lt; 12 years (n = 23), 17% were 12 to &lt; 18 years (n = 5); 57% had metastatic disease (n = 17) and 44% had locally advanced disease (n = 13); and all patients had received prior treatment for their cancer, including surgery, radiotherapy, or systemic therapy. The most common cancers were neuroblastoma (47%), primary CNS tumors (30%), and sarcoma (10%). The median duration of exposure for all pediatric patients was 4.2 months (range: 0.2 to 22.7 months).</p><p>Due to the small number of pediatric and adult patients, the single arm design of clinical studies of ROZLYTREK, and confounding factors such as differences in susceptibility to infections between pediatric and adult patients, it is not possible to determine whether the observed differences in the incidence of adverse reactions to ROZLYTREK are related to patient age or other factors. In an expanded safety database that included 338 adult patients and 30 pediatric patients who received ROZLYTREK across clinical trials, the Grade 3 or 4 adverse reactions and laboratory abnormalities that occurred more frequently (&ge; 5%) in pediatric patients (n = 30) compared with adults (n = 338) were neutropenia (27% vs 2%), bone fractures (23% vs 5%), increased weight (20% vs 7%), thrombocytopenia (10% vs 0.3%), lymphopenia (7% vs 1%), increased gamma-glutamyl transferase (7% vs 0%), and device-related infection (7% vs 0.3%). Three pediatric patients discontinued ROZLYTREK due to an adverse reaction (Grade 4 pulmonary edema, Grade 3 dyspnea, and Grade 4 pancreatitis).</p><p>The safety and effectiveness of ROZLYTREK in pediatric patients less than 12 years of age with solid tumors who have an <em>NTRK </em>gene fusion have not been established.</p><p>The safety and effectiveness of ROZLYTREK in pediatric patients with <em>ROS1</em>-positive NSCLC have not been established.</p><p><u>Juvenile Animal Toxicity Data</u></p><p>In a 13-week juvenile rat toxicology study, animals were dosed daily from post-natal day 7 to day 97 (approximately equivalent to neonate to adulthood). Entrectinib resulted in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased body weight gain and delayed sexual maturation at doses &ge; 4 mg/kg/day (approximately 0.06&nbsp;times the human exposure (AUC) at the 600 mg dose),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deficits in neurobehavioral assessments including functional observational battery and learning and memory (at doses &ge; 8 mg/kg/day, approximately 0.14 times the human exposure at the 600 mg dose), and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased femur length at doses &ge; 16 mg/kg/day (approximately 0.18 times the human exposure at the 600 mg dose).</p><p>&nbsp;</p><p><strong>Geriatric Use</strong></p><p>Of the 355 patients who received ROZLYTREK across clinical trials, 25% were 65 years or older, and 5% were 75 years of age or older. Clinical studies of ROZLYTREK did not include sufficient numbers of geriatric patients to determine whether they respond differently from younger patients.</p><p>&nbsp;</p><p><strong>Renal Impairment</strong></p><p>No dose adjustment is recommended for patients with mild or moderate renal impairment (CLcr 30 to &lt; 90 mL/min calculated by Cockcroft-Gault equation). ROZLYTREK has not been studied in patients with severe renal impairment (CLcr &lt; 30 mL/min) <em>[see Pharmacodynamic Properties (5.1)</em><em>].</em></p><p>&nbsp;</p><p><strong>Hepatic Impairment</strong></p><p>No dose adjustment is recommended for patients with mild (total bilirubin &le; 1.5 times ULN) hepatic impairment. ROZLYTREK has not been studied in patients with moderate (total bilirubin &gt; 1.5 to 3 times ULN) and severe (total bilirubin &gt; 3 times ULN) hepatic impairment <em>[see </em><em>Pharmacodynamic Properties (5.1)</em><em>].</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ROZLYTREK may influence the ability to drive and use machines. Patients should be instructed not to drive or use machines until the symptoms resolve, if they experience cognitive adverse reactions, syncope, blurred vision, or dizziness, during treatment with ROZLYTREK (<em>see section 4.4 and 4.8</em>)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ADVERSE REACTIONS</strong></p><p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congestive Heart Failure <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Central Nervous System Effects <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skeletal Fractures <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperuricemia <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QT Interval Prolongation <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision Disorders <em>[see </em><em>Special warnings and precautions for use</em><em> (4.4)]</em></p><p>&nbsp;</p><p><strong>Clinical Trial Experience</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>Data in WARNINGS AND PRECAUTIONS and below reflect exposure to ROZLYTREK in 355 patients, including 172 (48%) patients exposed for 6 months or longer and 84 (24%) patients exposed for 1 year or longer. ROZLYTREK was studied in one dose-finding trial in adults [ALKA (n = 57)], one dose-finding and activity-estimating trial in adults [STARTRK-1 (n = 76)], one dose-finding and activity-estimating trial in pediatric and adult patients [STARTRK-NG (n = 16)], and one single arm, activity-estimating trial in adults [STARTRK-2 (n = 206)].&nbsp;&nbsp;</p><p>The population characteristics were: median age 55 years (range: 4 to 86 years); 5% (n = 17) were less than 18 years of age; 55% were female; and 66% were White, 23% were Asian, and 5% were Black; 3% were Hispanic/Latino. The most common tumors (&ge; 5%) were lung (56%), sarcoma (8%), and colon (5%). <em>ROS1</em> gene fusions were present in 42% and <em>NTRK </em>gene fusions were present in 20%. Most adults (75%) received ROZLYTREK 600 mg orally once daily. The doses ranged from 100 mg/m<sup>2</sup> to 1600 mg/m<sup>2</sup> once daily in adults and 250 mg/m<sup>2</sup> to 750 mg/m<sup>2</sup> once daily in pediatric patients. ROZLYTREK is not indicated for pediatric patients less than 12 years of age <em>[</em><em>see </em><em>Fertility, pregnancy and lactation</em><em> (4.6)</em><em>]</em>.</p><p>Serious adverse reactions occurred in 39% of patients. The most frequent serious adverse reactions (&ge; 2%) were pneumonia (3.9%), dyspnea (3.7%), pleural effusion (3.4%), sepsis (2.5%), pulmonary embolism (2.3%), respiratory failure (2%), and pyrexia (2%). Grade 3 or 4 adverse reactions occurred in 60% of patients; the most common (&ge; 2%) were lung infection (5%), increased weight (7%), dyspnea (6%), fatigue/asthenia (5%), cognitive disorders (4.5%), syncope (2.5%), pulmonary embolism (3.4%), hypoxia (3.4%), pleural effusion (3.1%), hypotension (2.8%), diarrhea (2%), and urinary tract infection (2.5%). Fatal events included dyspnea (0.6%), pneumonia (0.6%), sepsis (0.6%), completed suicide (0.3%), large intestine perforation (0.3%) and tumor lysis syndrome (0.3%). One patient developed Grade 4 myocarditis after one dose of ROZLYTREK which resolved after discontinuation of ROZLYTREK and administration of high-dose corticosteroids.</p><p>Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received ROZLYTREK. The most frequent adverse reactions (&lt; 1% each) that resulted in permanent discontinuation were pneumonia, cardio-respiratory arrest, dyspnea, and fatigue.</p><p>Dose interruptions due to adverse reactions occurred in 46% of patients. The most frequent adverse reactions (&ge;&nbsp;2%) that resulted in interruption were increased blood creatinine (4%), fatigue (3.7%), anemia (3.1%), diarrhea (2.8%), pyrexia (2.8%), dizziness (2.5%), dyspnea (2.3%), nausea (2.3%), pneumonia (2.3%), cognitive disorder (2%) and neutropenia (2%).&nbsp;</p><p>Dose reductions due to adverse reactions occurred in 29% of patients who received ROZLYTREK. The most frequent adverse reactions resulting in dose reductions (&ge; 1%) were dizziness (3.9%), increased blood creatinine (3.1%), fatigue (2.3%), anemia (1.7%), and increased weight (1.4%).</p><p>The most common adverse reactions (&ge; 20%) were fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, dysesthesia, dyspnea, myalgia, cognitive impairment, increased weight, cough, vomiting, pyrexia, arthralgia and vision disorders.</p><p>Table 4 summarizes the adverse reactions observed in these 355 patients.</p><p><strong>Table&nbsp;4: Adverse Reactions (&ge; 10%) in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td rowspan="2"><p><strong>Adverse Reactions</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ROZLYTREK</strong></p><p><strong>N = 355</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades (%)</strong></p></td><td style="vertical-align:top"><p><strong>Grade &ge; 3* (%)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>General</strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>1</sup></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>Edema<sup>2</sup></p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal</strong></p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>46</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>3</sup></p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous System</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness<sup>4</sup></p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Dysesthesia<sup>5</sup></p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Cognitive impairment<sup>6</sup></p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>4.5</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral sensory neuropathy<sup>7</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Ataxia<sup>8</sup></p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Sleep<sup>9</sup></p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Mood disorders<sup>10</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>6*</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue</strong></p></td></tr><tr><td style="vertical-align:top"><p>Myalgia<sup>11</sup></p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and Nutritional</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased weight</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vision disorders<sup>12</sup></p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections </strong></p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>2.3</p></td></tr><tr><td style="vertical-align:top"><p>Lung infection<sup>13</sup></p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>6*</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension<sup>14</sup></p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>2.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>15</sup></p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Grades 3 &ndash; 5, inclusive of fatal adverse reactions, including 2 events of pneumonia and 2 events of dyspnea.</p><p><sup>1</sup>Includes fatigue, asthenia</p><p><sup>2</sup> Includes face edema, fluid retention, generalized edema, localized edema, edema, edema peripheral, peripheral swelling</p><p><sup>3 </sup>Includes abdominal pain upper, abdominal pain, lower abdominal discomfort, abdominal tenderness</p><p><sup>4</sup> Includes dizziness, vertigo, dizziness postural</p><p><sup>5</sup> Includes paresthesia, hyperesthesia, hypoesthesia, dysesthesia, oral hypoesthesia, palmar-plantar erythrodysesthesia, oral paresthesia, genital hypoesthesia</p><p><sup>6</sup> Includes amnesia, aphasia, cognitive disorder, confusional state, delirium, disturbance in attention, hallucinations, visual hallucination, memory impairment, mental disorder, mental status changes&nbsp;</p><p><sup>7</sup> Includes neuralgia, neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy</p><p><sup>8</sup> Includes ataxia, balance disorder, gait disturbances</p><p><sup>9</sup> Includes hypersomnia, insomnia, sleep disorder, somnolence</p><p><sup>10</sup> Includes anxiety, affect lability, affective disorder, agitation, depressed mood, euphoric mood, mood altered, mood swings, irritability, depression, persistent depressive disorder, psychomotor retardation</p><p><sup>11</sup> Includes musculoskeletal pain, musculoskeletal chest pain, myalgia, neck pain</p><p><sup>12</sup> Includes blindness, cataract, cortical cataract, corneal erosion, diplopia, eye disorder, photophobia, photopsia, retinal hemorrhage, vision blurred, visual impairment, vitreous adhesions, vitreous detachment, vitreous floaters</p><p><sup>13</sup> Includes lower respiratory tract infection, lung infection, pneumonia, respiratory tract infection</p><p><sup>14</sup> Includes hypotension, orthostatic hypotension</p><p><sup>15 </sup>Includes rash, rash maculopapular, rash pruritic, rash erythematous, rash papular</p></td></tr></tbody></table><p>Clinically relevant adverse reactions occurring in &le; 10% of patients include dysphagia (10%), fall (8%), pleural effusion (8%), fractures (6%), hypoxia (4.2%), pulmonary embolism (3.9%), syncope (3.9%), congestive heart failure (3.4%), and QT prolongation (3.1%)<em>.</em></p><p>&nbsp;</p><p>&nbsp;</p><p>Table 5 summarizes the laboratory abnormalities.</p><p><strong>Table 5: Laboratory Abnormalities (&ge; 20%) Worsening from Baseline in Patients Receiving ROZLYTREK in ALKA, STARTRK-1, STARTRK-2, and STARTRK-NG</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Laboratory Abnormality</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ROZLYTREK</strong></p><p><strong>NCI CTCAE Grade</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>All Grades (%)</strong><sup>1</sup></p></td><td style="vertical-align:top"><p><strong>Grade 3 or 4 (%)</strong><sup>1</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hematology</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>9</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Chemistry</strong></p></td></tr><tr><td style="vertical-align:top"><p>Increased creatinine<sup>2</sup></p></td><td style="vertical-align:top"><p>73</p></td><td style="vertical-align:top"><p>2.1</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricemia</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Increased AST</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>2.7</p></td></tr><tr><td style="vertical-align:top"><p>Increased ALT</p></td><td style="vertical-align:top"><p>38</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td style="vertical-align:top"><p>Hypernatremia</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphatemia</p></td><td style="vertical-align:top"><p>30</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>Increased lipase</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>10</p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminemia</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td style="vertical-align:top"><p>Increased amylase</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>5.4</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalemia</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>Increased alkaline phosphatase</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>0.9</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia<sup>3</sup></p></td><td style="vertical-align:top"><p>NE<sup>3</sup></p></td><td style="vertical-align:top"><p>3.8</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase</p><p><sup>1 </sup>Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available which ranged from 111 to 346 patients.</p><p><sup>2 </sup>Based on NCI CTCAE v5.0</p><p><sup>3 </sup>NE = Not evaluable. Grade 1 and 2 could not be determined per NCI CTCAE v5.0, as fasting glucose values were not collected.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>To report any side effect(s):</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>o&nbsp;&nbsp;&nbsp; SFDA call center: 19999</p><p>o&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdosage in clinical trials with ROZLYTREK. Patients who experience overdose should be closely supervised and supportive care instituted. There are no known antidotes for ROZLYTREK.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitor. ATC code: L01XE56.</p><p>&nbsp;</p><p><strong>Mechanism of Action:</strong></p><p>Entrectinib is an inhibitor of the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [<em>NTRK</em>] genes <em>NTRK1, NTRK2, </em>and<em> NTRK3</em>, respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK) with IC<sub>50</sub> values of 0.1 to 2 nM. Entrectinib also inhibits JAK2 and TNK2 with IC<sub>50</sub> values &gt; 5 nM. The major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK.</p><p>Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic potential through hyperactivation of downstream signaling pathways leading to unconstrained cell proliferation. Entrectinib demonstrated in vitro and in vivo inhibition of cancer cell lines derived from multiple tumor types harboring&nbsp;<em>NTRK</em>,&nbsp;<em>ROS1,</em>&nbsp;and&nbsp;<em>ALK</em>&nbsp;fusion genes.</p><p>Entrectinib demonstrated steady-state brain-to-plasma concentration ratios of 0.4 &ndash; 2.2 in multiple animal species (mice, rats, and dogs) and demonstrated in vivo anti-tumor activity in mice with intracranial implantation of TRKA- and ALK-driven tumor cell lines.&nbsp;</p><p><strong>Pharmacodynamics:</strong></p><p>Entrectinib exposure-response relationships and the time course of pharmacodynamic responses are unknown.</p><p><u>Cardiac Electrophysiology</u></p><p>Across clinical trials, 3.1% of 355 patients, who received ROZLYTREK at doses ranging from 100 mg to 2600 mg daily under fasting or fed conditions (75% received 600 mg orally once daily) and had at least one post-baseline ECG assessment, experienced QTcF interval prolongation of &gt; 60 ms after starting ROZLYTREK and 0.6% had a QTc interval &gt; 500 ms <em>[see Special warnings and precautions for use</em><em> (4.4)].</em></p><p><strong>&nbsp;</strong></p><p><strong>Clinical efficacy and safety (Clinical studies):</strong></p><p><strong><em>ROS1</em>-Positive Non-Small Cell Lung Cancer</strong></p><p>The efficacy of ROZLYTREK was evaluated in a pooled subgroup of patients with <em>ROS1</em>-positive metastatic NSCLC who received ROZLYTREK at various doses and schedules (90% received ROZLYTREK 600 mg orally once daily) and were enrolled in one of three multicenter, single-arm, open-label clinical trials: ALKA, STARTRK-1 (NCT02097810) and STARTRK-2 (NCT02568267). To be included in this pooled subgroup, patients were required to have histologically confirmed, recurrent or metastatic, <em>ROS1</em>-positive NSCLC, ECOG performance status &le; 2, measurable disease per RECIST v 1.1, &ge; 18 months of follow-up from first post-treatment tumor assessment, and no prior therapy with a ROS1 inhibitor. Identification of <em>ROS1</em> gene fusion in tumor specimens was prospectively determined in local laboratories using either a fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), or polymerase chain reaction (PCR) laboratory-developed tests. All patients were assessed for CNS lesions at baseline. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR) according to RECIST v1.1 as assessed by blinded independent central review (BICR). Intracranial response according to RECIST v1.1 was assessed by BICR. Tumor assessments with imaging were performed every 8 weeks.</p><p>Efficacy was assessed in 92 patients with <em>ROS1</em>-positive NSCLC. The median age was 53 years (range: 27 to 86); female (65%); White (48%), Asian (45%), and Black (5%); and Hispanic or Latino (2.4%); never smoked (59%); and ECOG performance status 0 or 1 (88%). Ninety-nine percent of patients had metastatic disease, including 42% with CNS metastases; 96% had adenocarcinoma; 65% received prior platinum-based chemotherapy for metastatic or recurrent disease and no patient had progressed in less than 6 months following platinum-based adjuvant or neoadjuvant therapy. <em>ROS1</em> positivity was determined by NGS in 79%, FISH in 16%, and PCR in 4%. Twenty-five percent had central laboratory confirmation of <em>ROS1</em> positivity using an analytically validated NGS test. &nbsp;</p><p>&nbsp;</p><p>Efficacy results are summarized in Table 6.</p><p><strong>Table 6: Efficacy Results in <em>ROS1</em>-Positive NSCLC Patients per BICR Assessment</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Efficacy Parameters</strong></p></td><td style="vertical-align:top"><p><strong>ROZLYTREK</strong></p><p><strong>N = 92</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Overall Response Rate</strong> (95% CI)</p></td><td style="vertical-align:bottom"><p>74% (64, 83)</p></td></tr><tr><td style="vertical-align:bottom"><p>Complete Response</p></td><td style="vertical-align:top"><p>15%</p></td></tr><tr><td style="vertical-align:bottom"><p>Partial Response</p></td><td style="vertical-align:top"><p>59%</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Duration of Response (DOR)*</strong></p></td><td style="vertical-align:top"><p><strong>N = 68</strong></p></td></tr><tr><td style="vertical-align:top"><p>Range (months)</p></td><td style="vertical-align:top"><p>2.4, 55.2+</p></td></tr><tr><td style="vertical-align:top"><p>% DOR &ge; 9 months</p></td><td style="vertical-align:top"><p>75%</p></td></tr><tr><td style="vertical-align:top"><p>% DOR &ge; 12 months</p></td><td style="vertical-align:top"><p>57%</p></td></tr><tr><td style="vertical-align:top"><p>% DOR &ge; 18 months</p></td><td style="vertical-align:top"><p>38%</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>Confidence Interval (CI) calculated using the Clopper-Pearson method.</p><p>* Observed DOR</p><p>+ denotes ongoing response</p></td></tr></tbody></table><p>Among the 92 patients, 10 had measurable CNS metastases at baseline as assessed by BICR and had not received radiation therapy to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 7 of these 10 patients.</p><p>&nbsp;</p><p><strong><em>NTRK</em> Gene Fusion-Positive Solid Tumors</strong></p><p>The efficacy of ROZLYTREK was evaluated in a pooled subgroup of adult patients with unresectable or metastatic solid tumors with a <em>NTRK </em>gene fusion enrolled in one of three multicenter, single-arm, open-label clinical trials: ALKA, STARTRK-1 (NCT02097810) and STARTRK-2 (NCT02568267). To be included in this pooled subgroup, patients were required to have progressed following systemic therapy for their disease, if available, or would have required surgery causing significant morbidity for locally advanced disease; measurable disease per RECIST v1.1; at least 2 years of follow-up from first post-treatment tumor assessment; and no prior therapy with a TRK inhibitor. Patients received ROZLYTREK at various doses and schedules (94% received ROZLYTREK 600 mg orally once daily) until unacceptable toxicity or disease progression. Identification of positive <em>NTRK</em> gene fusion status was prospectively determined in local laboratories or a central laboratory using various nucleic acid-based tests. The major efficacy outcome measures were ORR and DOR, as determined by a BICR according to RECIST v1.1. Intracranial response according to RECIST v1.1 as evaluated by BICR. Tumor assessments with imaging were performed every 8 weeks.</p><p>Efficacy was assessed in the first 54 adult patients with solid tumors with an <em>NTRK </em>gene fusion enrolled into these trials. The median age was 58 years (range: 21 to 83); female (59%); White (80%), Asian (13%) and Hispanic or Latino (7%); and ECOG performance status 0 (43%) or 1 (46%). Ninety-six percent of patients had metastatic disease, including 22% with CNS metastases, and 4% had locally advanced, unresectable disease. All patients had received prior treatment for their cancer including surgery (n = 43), radiotherapy (n = 36), or systemic therapy (n = 48). Forty patients (74%) received prior systemic therapy for metastatic disease with a median of 1 prior systemic regimen and 17% (n = 9) received 3 or more prior systemic regimens. The most common cancers were sarcoma (24%), lung cancer (19%), salivary gland tumors (13%), breast cancer (11%), thyroid cancer (9%), and colorectal cancer (7%). A total of 52 (96%) patients had an <em>NTRK</em> gene fusion detected by NGS and 2 (4%) had an <em>NTRK</em> gene fusion detected by other nucleic acid-based tests. Eighty-three percent of patients had central laboratory confirmation of <em>NTRK</em> gene fusion using an analytically validated NGS test.</p><p>&nbsp;</p><p>Efficacy results are summarized in Tables 7, 8, and 9.</p><p><strong>Table 7: Efficacy Results for Patients with Solid Tumors Harboring <em>NTRK</em> Gene Fusions </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Efficacy Parameter</strong></p></td><td><p><strong>ROZLYTREK</strong></p><p><strong>N = 54</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Overall Response Rate</strong> (95% CI)</p></td><td style="vertical-align:bottom"><p>59% (45, 72)</p></td></tr><tr><td style="vertical-align:bottom"><p>Complete Response</p></td><td style="vertical-align:bottom"><p>13%</p></td></tr><tr><td style="vertical-align:bottom"><p>Partial Response</p></td><td style="vertical-align:bottom"><p>46%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of Response*</strong></p></td><td style="vertical-align:top"><p><strong>N = 32</strong></p></td></tr><tr><td style="vertical-align:top"><p>Range (months)</p></td><td style="vertical-align:top"><p>2.8, 47.8+</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge; 6 months</p></td><td style="vertical-align:top"><p>72%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge; 9 months</p></td><td style="vertical-align:top"><p>66%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge; 12 months</p></td><td style="vertical-align:top"><p>56%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Observed DOR<sup> </sup></p><p>+ denotes ongoing response</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 8: Efficacy by Tumor Type </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:82%"><tbody><tr><td rowspan="2"><p><strong>Tumor Type </strong></p></td><td rowspan="2"><p><strong>Patients</strong></p><p><strong>N = 54</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ORR</strong></p></td><td style="vertical-align:top"><p><strong>DOR</strong></p></td></tr><tr><td><p><strong>%</strong></p></td><td><p><strong>95% CI</strong></p></td><td style="vertical-align:top"><p><strong>Range</strong></p><p><strong>(months)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sarcoma</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>46%</p></td><td style="vertical-align:top"><p>19%, 75%</p></td><td style="vertical-align:top"><p>2.8, 33.6+</p></td></tr><tr><td style="vertical-align:top"><p>Non-small cell lung cancer</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>60%</p></td><td style="vertical-align:top"><p>26%, 88%</p></td><td style="vertical-align:top"><p>3.7, 47.8+</p></td></tr><tr><td style="vertical-align:top"><p>Salivary (MASC)</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>86%</p></td><td style="vertical-align:top"><p>42%, 100%</p></td><td style="vertical-align:top"><p>2.8, 38.5+</p></td></tr><tr><td style="vertical-align:top"><p>Breast cancer</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>83%</p></td><td style="vertical-align:top"><p>36%, 100%</p></td><td style="vertical-align:top"><p>4.2, 42.3+</p></td></tr><tr><td style="vertical-align:top"><p>Thyroid cancer</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>60%</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>7.9, 31.5+</p></td></tr><tr><td style="vertical-align:top"><p>Colorectal cancer</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>25%</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>15.1</p></td></tr><tr><td style="vertical-align:top"><p>Neuroendocrine cancers</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>32.9+</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatic cancer</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>PR, PR</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>7.1, 12.9</p></td></tr><tr><td style="vertical-align:top"><p>Gynecological cancers</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>38.2</p></td></tr><tr><td style="vertical-align:top"><p>Cholangiocarcinoma</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>9.3</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>+ denotes ongoing response</p><p>MASC: mammary analogue secretory carcinoma; NA = not applicable; PR = partial response.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;Table 9: Efficacy Results by <em>NTRK</em> Gene Fusion Partner</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2"><p><strong><em>NTRK</em></strong><strong> Partner</strong></p></td><td rowspan="2"><p><strong>Patients</strong></p><p><strong>N = 54</strong></p></td><td colspan="2"><p><strong>ORR</strong></p></td><td><p><strong>DOR</strong></p></td></tr><tr><td><p><strong>%</strong></p></td><td><p><strong>95% CI</strong></p></td><td><p><strong>Range (months)</strong></p></td></tr><tr><td><p>ETV6 &ndash; NTRK3</p></td><td><p>25</p></td><td><p>72%</p></td><td><p>51%, 88%</p></td><td><p>2.8, 47.8+</p></td></tr><tr><td><p>TPM3 &ndash; NTRK1</p></td><td><p>4</p></td><td><p>50%</p></td><td><p>7%, 93%</p></td><td><p>2.8, 15.1</p></td></tr><tr><td><p>TPR &ndash; NTRK1</p></td><td><p>4</p></td><td><p>100%</p></td><td><p>40%, 100%</p></td><td><p>5.6, 33.6+</p></td></tr><tr><td><p>LMNA &ndash; NTRK1</p></td><td><p>2</p></td><td><p>PR, PD</p></td><td><p>NA</p></td><td><p>4.2</p></td></tr><tr><td><p>SQSTM1 &ndash; NTRK1</p></td><td><p>2</p></td><td><p>PR, PD</p></td><td><p>NA</p></td><td><p>18.8+</p></td></tr><tr><td><p>PEAR1 &ndash; NTRK1</p></td><td><p>2</p></td><td><p>SD, NE</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>EML4 &ndash; NTRK3</p></td><td><p>2</p></td><td><p>PR, NE</p></td><td><p>NA</p></td><td><p>13.2</p></td></tr><tr><td><p>CD74 &ndash; NTRK1</p></td><td><p>1</p></td><td><p>PR</p></td><td><p>NA</p></td><td><p>10.4</p></td></tr><tr><td><p>PLEKHA6 &ndash; NTRK1</p></td><td><p>1</p></td><td><p>PR</p></td><td><p>NA</p></td><td><p>9.3</p></td></tr><tr><td><p>CDC42BPA &ndash; NTRK1</p></td><td><p>1</p></td><td><p>PR</p></td><td><p>NA</p></td><td><p>29.4</p></td></tr><tr><td><p>EPS15L1 &ndash; NTRK1</p></td><td><p>1</p></td><td><p>PR</p></td><td><p>NA</p></td><td><p>3.7</p></td></tr><tr><td><p>RBPMS &ndash; NTRK3</p></td><td><p>1</p></td><td><p>PR</p></td><td><p>NA</p></td><td><p>4.6</p></td></tr><tr><td><p>ERC1 &ndash; NTRK1</p></td><td><p>1</p></td><td><p>SD</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>PDIA3 &ndash; NTRK1</p></td><td><p>1</p></td><td><p>SD</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>TRIM33 &ndash; NTRK1</p></td><td><p>1</p></td><td><p>SD</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>AKAP13 &ndash; NTRK3</p></td><td><p>1</p></td><td><p>SD</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>KIF7 &ndash; NTRK3</p></td><td><p>1</p></td><td><p>SD</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>FAM19A2 &ndash; NTRK3</p></td><td><p>1</p></td><td><p>PD</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>CGN &ndash; NTRK1</p></td><td><p>1</p></td><td><p>NE</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td><p>SQSTM1 &ndash; NTRK2</p></td><td><p>1</p></td><td><p>NE</p></td><td><p>NA</p></td><td><p>NA</p></td></tr><tr><td colspan="5"><p>+ denotes ongoing response</p><p>PR = partial response; PD = progressive disease; SD = stable disease; NA = not applicable; NE = not evaluable.</p></td></tr></tbody></table><p>Among the subset of patients who received prior systemic therapy for metastatic disease, the ORR was 53%, similar to that seen in the overall population. Among the 54 adult patients, 4 had measurable CNS metastases at baseline as assessed by BICR and had not received radiation therapy to the brain within 2 months of study entry. Responses in intracranial lesions were observed in 3 of these 4 patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics for entrectinib and its pharmacologically active major circulating metabolite M5 were characterized in adult patients with <em>ROS1</em>-positive NSCLC, <em>NTRK</em> gene fusion-positive solid tumors, and healthy subjects. The pharmacokinetics of entrectinib and M5 are linear and are not dose-dependent or time-dependent. Steady state is achieved within one week for entrectinib and two weeks for M5 following daily administration of ROZLYTREK. The pharmacokinetic parameters for entrectinib and M5 are described in Table 10.</p><p>&nbsp;</p><p><strong>Table 10: Pharmacokinetic Parameters for Entrectinib and Metabolite M5</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Parameter</strong></p></td><td><p><strong>Entrectinib</strong></p><p><strong>Mean* (% CV)</strong></p></td><td><p><strong>M5</strong></p><p><strong>Mean* (% CV)</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>D1 </sub>(nM*h)</p></td><td style="vertical-align:top"><p>31800 (48%)</p></td><td style="vertical-align:top"><p>10200 (82%)</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>ss</sub> (nM*h)</p></td><td style="vertical-align:top"><p>48000 (77%)</p></td><td style="vertical-align:top"><p>24000 (97%)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>maxD1</sub> (nM)</p></td><td style="vertical-align:top"><p>2250 (58%)</p></td><td style="vertical-align:top"><p>622 (79%)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>maxss</sub> (nM)</p></td><td style="vertical-align:top"><p>3130 (80%)</p></td><td style="vertical-align:top"><p>1250 (90%)</p></td></tr><tr><td style="vertical-align:top"><p>R<sub>acc(AUC)</sub></p></td><td style="vertical-align:top"><p>1.55 (49%)</p></td><td style="vertical-align:top"><p>2.84 (93%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Geometric mean</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Absorption</u></p><p>The maximum entrectinib plasma concentration was reached 4 &ndash; 6 hours after oral administration of a 600 mg dose.</p><p><em>Effect of Food</em></p><p>A high-fat (approximately 50% of total caloric content), high-calorie (approximately 800 to 1000 calories) meal did not have a significant effect on entrectinib exposure.</p><p><u>Distribution</u></p><p>Entrectinib and its active major metabolite M5 are both &gt; 99% bound to human plasma proteins in vitro.</p><p>The estimated apparent volume of distribution (V/F) was 551 L and 81.1 L for entrectinib and M5, respectively. &nbsp;&nbsp;</p><p><u>Elimination</u></p><p>The estimated apparent clearance (CL/F) was 19.6 L/h and 52.4 L/h for entrectinib and M5, respectively. The elimination half-lives of entrectinib and M5 were estimated to be 20 and 40 hours, respectively.</p><p><em>Metabolism</em></p><p>Entrectinib is metabolized primarily by CYP3A4 (~76%). The active metabolite M5 (formed by CYP3A4) is the only major active circulating metabolite identified. M5 has similar pharmacological potency to entrectinib in vitro and circulating M5 exposures at steady-state in patients were 40% of the corresponding entrectinib exposure.</p><p><em>Excretion</em></p><p>Following oral administration of a single oral dose of [<sup>14</sup>C]-labeled entrectinib, 83% of radioactivity was excreted in feces (36% of the dose as unchanged entrectinib and 22% as M5) with minimal excretion in urine (3%).</p><p><u>Specific Populations</u></p><p>No clinically significant differences in the pharmacokinetics of entrectinib were observed based on age (12 years to 86 years), sex, race (White, Asian and Black), body weight (32 to 130 kg), mild to moderate renal impairment (CLcr 30 to &lt; 90 mL/min) and mild hepatic impairment (total bilirubin &le; 1.5 times ULN). The impact of moderate to severe hepatic impairment or severe renal impairment on the pharmacokinetics of entrectinib is unknown.</p><p><em>Pediatric Patients</em></p><p>The predicted systemic exposures for body surface area-based doses of 600 mg (BSA &gt; 1.50 m<sup>2</sup>), 500 mg (BSA of 1.11 to 1.50 m<sup>2</sup>) and 400 mg (BSA of 0.91 to 1.10 m<sup>2</sup>) in pediatric patients 12 years and older are comparable to the exposure in adults at the 600 mg dose <em>[</em><em>see </em><em>Fertility, pregnancy and lactation</em><em> (4.6)</em><em>]</em>.</p><p><u>Drug Interaction Studies</u></p><p><em>Clinical Studies </em></p><p><em>Effect of CYP3A Inhibitors on Entrectinib:</em> Coadministration of itraconazole (a strong CYP3A inhibitor) with a single 100 mg ROZLYTREK dose increased entrectinib AUC<sub>0-INF</sub> by 6-fold and C<sub>max</sub> by 1.7-fold <em>[see </em><em>Interaction with other medicinal products and other forms of interaction (</em><em>4.5)</em><em>]</em>. Coadministration of a moderate CYP3A inhibitor with ROZLYTREK is predicted to increase entrectinib AUC<sub>0-Tau</sub> by 3-fold and C<sub>max</sub> by 2.9-fold.</p><p><em>Effect of CYP3A Inducers on Entrectinib: </em>Coadministration of rifampin (a strong CYP3A inducer) with a single 600 mg ROZLYTREK dose reduced entrectinib AUC<sub>0-INF</sub> by 77% and C<sub>max</sub> by 56% <em>[see </em><em>Interaction with other medicinal products and other forms of interaction (</em><em>4.5)</em><em>].</em> Coadministration of a moderate CYP3A inducer with ROZLYTREK is predicted to reduce entrectinib AUC<sub>0-Tau</sub> by 56% and C<sub>max</sub> by 43%.</p><p><em>Effect of Gastric Acid Reducing Drugs on Entrectinib</em>: Coadministration of a proton pump inhibitor (PPI), lansoprazole with a single 600 mg ROZLYTREK dose reduced entrectinib AUC by 25% and C<sub>max</sub> by 23%.<sub> </sub></p><p><em>Effect of Entrectinib on CYP Substrates</em>: Coadministration of ROZLYTREK 600 mg once daily with oral midazolam (a sensitive CYP3A substrate) in patients increased the midazolam AUC by 50% but reduced midazolam C<sub>max</sub> by 21% <em>[see </em><em>Interaction with other medicinal products and other forms of interaction</em><em> (</em><em>4.5)</em><em>]</em>.</p><p><em>Effect of Entrectinib on Transporters: </em>Coadministration of a single 600 mg ROZLYTREK dose with digoxin [a sensitive P-glycoprotein (P-gp) substrate] increased digoxin C<sub>max</sub> by 28% and AUC by 18%.</p><p><em>In Vitro Studies</em></p><p>Entrectinib is not a substrate of P-gp or BCRP, but M5 is a substrate of P-gp and BCRP. Entrectinib and M5 are not substrates of OATP1B1 or OATP1B3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility:</strong></p><p>Carcinogenicity studies were not conducted with entrectinib. Entrectinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay; however, an in vitro assay in cultured human peripheral blood lymphocytes did demonstrate a potential for abnormal chromosome segregation (aneugenicity). Entrectinib was not clastogenic or aneugenic in the in vivo micronucleus assay in rats and did not induce DNA damage in a comet assay in rats.&nbsp;</p><p>Dedicated fertility studies were not conducted with entrectinib. With the exception of dose-dependent decreases in prostate weight in male dogs, there were no effects on male and female reproductive organs observed in general toxicology studies conducted in rats and dogs at doses resulting in exposures of up to approximately 3.2 fold the human exposure (AUC) at the 600 mg dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inactive ingredients are tartaric acid, lactose anhydrous, hypromellose, crospovidone, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C (86&deg;F).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100 mg hard capsules: Size 2 yellow opaque, with &ldquo;ENT 100&rdquo; printed in blue ink; available in:</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; HDPE bottles of 30 capsules: NDC 50242-091-30</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 200 mg hard capsules: Size 0 orange opaque, with &ldquo;ENT 200&rdquo; printed in blue ink; available in:</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; HDPE bottles of 90 capsules: NDC 50242-094-90</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                F. Hoffmann-La Roche Ltd,
Grenzacherstrasse 124, 
CH-4070 Basel, 
Switzerland.

MARKETING AUTHORISATION NUMBER(S): 
100mg: 0301221550
200mg: 0301221552

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION:
Date of first authorisation: 02 January 2022.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21 November 2021. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>